Innovation - solid tumor therapy breakthrough

LMP1188 （Phase II）

The novel clinical-stage tumor microenvironment modulator LMP1188 primes solid tumors for anti-cancer therapy. The bifunctional cyclic peptide homes to normally difficult to reach solid tumors via RGD motif interaction with av-integrins and then transforms the solid tumor microenvironment into a temporary drug conduit via interaction with neuropilin-1 (NRP-1), leading to a better delivery and efficacy of most types of co-administered anti-cancer agents. The impact is especially dramatic in hard-to-treat solid tumors like e.g. pancreatic, gastric, breast and liver cancer. In addition to "opening up" solid tumors in such way, the technology also turns cold tumors hot by allowing efficient infiltration of immune cells into the tumor.

Preclinical combination therapy with LMP1188 has been extensively validated by various academic partners and shown to be efficacious against a variety of solid tumor types (including breast cancer, gastric cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, prostate cancer) and with a variety of different anti-cancer therapeutics, including monoclonal antibodies (anti-HER2), cytokines (IL-2), RNAi (anti-KRAS), small molecules (kinase inhibitors (EGFR inhibitors, VEGF, PDGFR, RAF inhibitors), taxanes, DNA synthesis inhibitors, topoisomerase I and II inhibitors) and nanoparticles. The delivery benefit can be more than 40-fold. The technology can also be used to make adaptive immune cell therapies (CAR-T, NK) solid tumor homing / tumor penetrating.

The combination principle is simple: all types of solid tumors can be primed for anti-cancer drugs by systemic co-administration – no drug modification (conjugation) needed. This leads to an improved the therapeutic index, i.e. increased dose efficiency – reduced toxicity
LMP1188 also has potential with adoptive cell therapies: both engineering and co-administration of LMP1188 with adoptive cell therapy enhances delivery and therapeutic efficacy of adoptive cell therapy. LMP1188 promotes tumor-specific lymphocyte infiltration and causes an increased an sustained increase in tumor-infiltrated T-cells through modification of T-cells.

Potential applications
Solid tumor combination therapy with - including but not limited to - adoptive cell immunotherapy like CAR-T and NK cell therapy, antibody drug conjugates, cytokines, monoclonal antibodies, nanoparticles, RNAi and small molecules